PMID- 20166128
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20100526
IS  - 1097-0045 (Electronic)
IS  - 0270-4137 (Linking)
VI  - 70
IP  - 10
DP  - 2010 Jul 1
TI  - Effect of intermittent fasting with or without caloric restriction on prostate 
      cancer growth and survival in SCID mice.
PG  - 1037-43
LID - 10.1002/pros.21136 [doi]
AB  - INTRODUCTION: Caloric restriction (CR) delays cancer growth in animals, though 
      translation to humans is difficult. We hypothesized intermittent fasting (i.e., 
      intermittent extreme CR), may be better tolerated and prolong survival of 
      prostate cancer (CaP) bearing mice. METHODS: We conducted a pilot study by 
      injecting 105 male individually-housed SCID mice with LAPC-4 cells. When tumors 
      reached 200 mm(3), 15 mice/group were randomized to one of seven diets and 
      sacrificed when tumors reached 1,500 mm(3): Group 1: ad libitum 7 days/week; 
      Group 2: fasted 1 day/week and ad libitum 6 days/week; Group 3: fasted 1 day/week 
      and fed 6 days/week via paired feeding to maintain isocaloric conditions to Group 
      1; Group 4: 14% CR 7 days/week; Group 5: fasted 2 days/week and ad libitum 5 
      days/week; Group 6: fasted 2 day/week and fed 5 days/week via paired feeding to 
      maintain isocaloric conditions to Group 1; Group 7: 28% CR 7 days/week. Sera from 
      mice at sacrifice were analyzed for IGF-axis hormones. RESULTS: There were no 
      significant differences in survival among any groups. However, relative to Group 
      1, there were non-significant trends for improved survival for Groups 3 (HR 0.65, 
      P = 0.26), 5 (0.60, P = 0.18), 6 (HR 0.59, P = 0.16), and 7 (P = 0.59, P = 0.17). 
      Relative to Group 1, body weights and IGF-1 levels were significantly lower in 
      Groups 6 and 7. CONCLUSIONS: This exploratory study found non-significant trends 
      toward improved survival with some intermittent fasting regimens, in the absence 
      of weight loss. Larger appropriately powered studies to detect modest, but 
      clinically important differences are necessary to confirm these findings.
FAU - Buschemeyer, W Cooper 3rd
AU  - Buschemeyer WC 3rd
AD  - Division of Urology, and the Duke Prostate Center, Department of Surgery, Duke 
      University Medical Center, Durham, North Carolina 27710, USA.
FAU - Klink, Joseph C
AU  - Klink JC
FAU - Mavropoulos, John C
AU  - Mavropoulos JC
FAU - Poulton, Susan H
AU  - Poulton SH
FAU - Demark-Wahnefried, Wendy
AU  - Demark-Wahnefried W
FAU - Hursting, Stephen D
AU  - Hursting SD
FAU - Cohen, Pinchas
AU  - Cohen P
FAU - Hwang, David
AU  - Hwang D
FAU - Johnson, Tracy L
AU  - Johnson TL
FAU - Freedland, Stephen J
AU  - Freedland SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Animals
MH  - Body Composition/physiology
MH  - Body Weight/physiology
MH  - Cell Growth Processes/physiology
MH  - Fasting/*physiology
MH  - Insulin-Like Growth Factor Binding Proteins/blood
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Male
MH  - Mice
MH  - Mice, SCID
MH  - Pilot Projects
MH  - Proportional Hazards Models
MH  - Prostatic Neoplasms/metabolism/*pathology
MH  - Random Allocation
MH  - Survival Analysis
EDAT- 2010/02/19 06:00
MHDA- 2010/06/16 06:00
CRDT- 2010/02/19 06:00
PHST- 2010/02/19 06:00 [entrez]
PHST- 2010/02/19 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
AID - 10.1002/pros.21136 [doi]
PST - ppublish
SO  - Prostate. 2010 Jul 1;70(10):1037-43. doi: 10.1002/pros.21136.